Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

769.11 +20.39 (+2.72%)
Streaming Delayed Price Updated: 2:10 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
News headline image
These S&P500 stocks that are showing activity before the opening bell on Tuesday. ↗
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Regeneron's Q3 Earnings Outperform Expectations With Dupixent Strength Balancing Eylea Weakness ↗
Regeneron posts Q3 earnings of $11.83 per share, topping estimates as Dupixent profits lift results despite weaker Eylea sales. 
Via Benzinga
News headline image
Regeneron's Earnings Took A Big Tax Hit, And Still Pounded Forecasts ↗
Regeneron stock advanced early Tuesday on better-than-expected third-quarter earnings despite a big tax hit. 
Via Investor's Business Daily
News headline image
Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 2025 Earnings Beat Estimates ↗
Regeneron (REGN) Q3 2025 earnings beat estimates with $11.83 EPS on $3.75B revenue. Strong performance driven by Dupixent and Libtayo sales growth. 
Via Chartmill
Topics Earnings
News headline image
Earnings Scheduled For October 28, 2025 ↗
 
Via Benzinga
Gapping S&P500 stocks in Monday's session ↗
Via Chartmill
Why Regeneron Pharmaceuticals’ Stock Is Climbing Premarket Today ↗
Via Stocktwits
News headline image
Regeneron (NASDAQ:REGN) Surprises With Strong Q3
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per share was... 
Via StockStory
News headline image
Regeneron Reports Third Quarter 2025 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Market's Perilous Peak: Is the U.S. Stock Market More Overvalued Than Ever?
New York, NY – October 27, 2025 – A chorus of concern is growing louder across financial markets, with prominent voices like MarketWatch raising alarm bells over what they describe as an unprecedented... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
A Preview Of Regeneron Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Regeneron Earnings: What To Look For From REGN
Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Sanofi Soars as Dupixent Sales Near €5 Billion Amidst Intensifying Trump Drug Pricing Negotiations
Paris, France – October 24, 2025 – Pharmaceutical giant Sanofi (EURONEXT: SAN, NASDAQ: SNY) saw its shares climb today following the announcement of stellar third-quarter 2025 financial results,... 
Via MarketMinute
Topics Government World Trade
News headline image
Immuno-Oncology Stocks Q2 Recap: Benchmarking Exact Sciences (NASDAQ:EXAS)
Looking back on immuno-oncology stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Reflecting On Immuno-Oncology Stocks’ Q2 Earnings: Natera (NASDAQ:NTRA)
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Natera (NASDAQ:NTRA) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
The FDA Just Granted Its Speediest Review Ever. Disc Medicine, Others Fly. ↗
The Commissioner's National Priority Review vouchers aims to speed up the review process to just one to two months. 
Via Investor's Business Daily
News headline image
FDA Unveils First Experimental Drugs Under Fast-Track Voucher Plan To Cut Drug Review Times ↗
The FDA launched a new voucher program to fast-track reviews, naming nine experimental drugs for cancer, diabetes, addiction, and other conditions. 
Via Benzinga
News headline image
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma (CSCC) with a High Risk of Recurrence After Surgery and Radiation
Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program ↗
The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks. 
Via Stocktwits
News headline image
Regeneron Pharmaceuticals (NASDAQ:REGN) Presents a Compelling Case for Value Investors ↗
Regeneron (REGN) presents a strong value investment case with a low P/E ratio, robust financial health, high profitability, and steady growth. 
Via Chartmill
News headline image
EyePoint Pharmaceuticals Raises Capital As It Advances Lead Product To Pivotal Study ↗
EyePoint Pharmaceuticals outlines Phase 3 trials for Duravyu in diabetic macular edema, backed by $150 million in new funding. 
Via Benzinga
News headline image
Regeneron Showcases Advances Across Oncology Portfolio and Pipeline at ESMO, Highlighting Novel and Patient-Focused Approach for Difficult-to-Treat Cancers
New safety and pharmacokinetic data from Phase 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk cutaneous squamous cell carcinoma 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
2 Stocks Down 17% and 21% to Buy Right Now ↗
Both companies have faced recent challenges, but look likely to overcome them. 
Via The Motley Fool
Topics World Trade
News headline image
Why Are Regeneron And Scholar Rock Shares Falling On Monday? ↗
Regeneron and Scholar Rock’s submissions have been delayed or denied following an FDA inspection at the third-party fill-finish facility Catalent Indiana, owned by Novo Nordisk. 
Via Stocktwits
News headline image
Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss ↗
Regeneron gene therapy for OTOF-related hearing loss shows rapid, sustained improvements, including normal hearing in some participants. 
Via Benzinga
News headline image
DB-OTO Results in the New England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 9 Analyst Projections For Regeneron Pharmaceuticals ↗
 
Via Benzinga
News headline image
Regeneron's Libtayo Gains FDA Approval To Reduce Recurrence Risk In Skin Cancer Patients ↗
FDA approves Regeneron's Libtayo for adults with high-risk cutaneous squamous cell carcinoma after surgery and radiation, based on Phase 3 trial data. 
Via Benzinga
News headline image
Investors Brace for Pullback as Short-Bias ETF Inflows Signal Growing Bearishness
A significant surge in capital flowing into short-bias Exchange-Traded Funds (ETFs) has sent a clear signal through the financial markets: investor sentiment is shifting towards caution and a potential... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.